Pulmonary Function Tests (PFTs) are integral to diagnosing and monitoring respiratory diseases. However, their interpretation can be complex, requiring a comprehensive understanding of pulmonary physiology and pathology. This article provides a concise guide for healthcare professionals to interpret PFT results accurately.
The primary parameters evaluated in PFTs include Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and the FEV1/FVC ratio. FVC reflects the maximum volume of air that can be forcefully exhaled after a full inhalation. FEV1 signifies the volume exhaled in the first second of this manoeuvre. The FEV1/FVC ratio is a critical index to distinguish obstructive from restrictive lung diseases.
An obstructive pattern is characterized by a reduced FEV1/FVC ratio (<70%) with a normal or increased FVC. This pattern is indicative of diseases like COPD or asthma. A restrictive pattern, on the other hand, is signified by a normal or increased FEV1/FVC ratio with a reduced FVC, suggesting conditions like pulmonary fibrosis or chest wall disorders.
The Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) is another crucial PFT parameter. It assesses the gas exchange function of the lungs. A reduced DLCO may suggest diseases affecting the alveolar-capillary interface, like emphysema or interstitial lung disease.
Interpreting PFTs is a nuanced process that requires a deep understanding of the parameters and their clinical implications. Accurate interpretation can lead to timely diagnosis and appropriate management of respiratory diseases. Continuous education and practice are key to mastering this critical skill in respiratory medicine.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation